Integer Holdings Co. (NYSE:ITGR) Short Interest Update

Integer Holdings Co. (NYSE:ITGR - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,660,000 shares, a growth of 19.8% from the February 28th total of 2,220,000 shares. Approximately 8.2% of the shares of the company are sold short. Based on an average daily volume of 370,400 shares, the short-interest ratio is currently 7.2 days.

Institutional Trading of Integer

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Integer in the fourth quarter valued at approximately $208,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Integer in the fourth quarter valued at approximately $7,889,000. Brucke Financial Inc. acquired a new position in shares of Integer in the fourth quarter worth $564,000. Azzad Asset Management Inc. ADV raised its stake in Integer by 4.9% in the 4th quarter. Azzad Asset Management Inc. ADV now owns 12,138 shares of the medical equipment provider's stock valued at $1,609,000 after purchasing an additional 566 shares during the last quarter. Finally, Vise Technologies Inc. lifted its stake in shares of Integer by 8.3% during the fourth quarter. Vise Technologies Inc. now owns 4,702 shares of the medical equipment provider's stock valued at $623,000 after buying an additional 362 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Trading Down 0.8 %

Shares of ITGR traded down $0.87 during midday trading on Monday, reaching $112.83. The company had a trading volume of 194,251 shares, compared to its average volume of 332,328. Integer has a 1-year low of $104.73 and a 1-year high of $146.36. The stock has a market cap of $3.79 billion, a PE ratio of 33.51, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. The firm has a 50 day simple moving average of $128.00 and a 200-day simple moving average of $131.75. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Research analysts forecast that Integer will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Oppenheimer lowered shares of Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Raymond James started coverage on Integer in a research note on Friday, March 28th. They issued an "outperform" rating and a $145.00 price target for the company. Benchmark boosted their price objective on Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Truist Financial increased their target price on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Finally, KeyCorp boosted their price target on Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $148.56.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.